Your browser does not support JavaScript!

Transforming Korea's Medical Industry: Performance, Trends, and Future Prospects

General Report May 8, 2025
goover

TABLE OF CONTENTS

  1. Summary
  2. Recent Market Performance and Export Dynamics
  3. Growth Projections and Global Positioning
  4. Major Corporate Investments Amid Industry Downturn
  5. Innovation through Digital Transformation
  6. Industry Collaboration and Events
  7. Conclusion

1. Summary

  • As of May 8, 2025, South Korea's medical and bio-health industry is on a dynamic trajectory characterized by recent fluctuations in market performance and promising growth projections. In the fiscal year 2023, the bio-health sector as a whole faced a minor decline of 0.7% in total sales, culminating in 133 trillion won (approximately $93.3 billion). However, distinct segments within the industry such as pharmaceuticals and cosmetics exhibited notable resilience. The pharmaceutical sector, for instance, thrived with revenues of 53.8 trillion won—marking a 6.1% year-on-year growth—while cosmetics sales surged by 7.9% to 42 trillion won, showcasing the adaptability of these markets to evolving consumer demands. In sharp contrast, the medical devices sector suffered a significant downturn, with a staggering 15.7% decline that serves as a stark reminder of the disparate impacts of market forces within the bio-health landscape.

  • The year 2024 reversed the industry's downturn with a remarkable rebound in health exports, which soared to $25.26 billion—a 15.8% increase from the previous year—driven primarily by biopharmaceuticals and skincare products that captured robust international demand. Particularly noteworthy was the biopharmaceutical segment's export growth, which reached $9.27 billion, bolstered by the U.S. market's increasing receptivity. The strategic diversification of the export portfolio was critical, exemplified by the remarkable 306.3% increase in biopharmaceutical exports to Hungary. The compelling performance of the cosmetics sector echoed this trend, with exports finally eclipsing the $10 billion mark, emphasizing Korea's growing relevance in the global beauty market. These growth trajectories reveal that, despite specific setbacks, the bio-health sector's core segments are positioned for substantial expansion.

  • Looking towards future prospects, analyses underscore South Korea’s ambition to become the eighth-largest biohealth market by 2030, projected to reach around $370.3 billion, reflecting a compound annual growth rate (CAGR) of nearly 9%. This optimistic outlook is underpinned by strategic investments totaling KRW 7.5 trillion by leading firms like Samsung Biologics and SK Bioscience—both of which are committed to bolstering capacity and technological innovation amidst industry challenges. The anticipation surrounding the upcoming Bio Korea 2025 event illustrates the sector's focus on innovation and collaboration, further establishing South Korea as a pivotal player in the global bio-health scene.

2. Recent Market Performance and Export Dynamics

  • 2-1. 2023 Domestic Sales Trends

  • In 2023, South Korea's bio-health industry experienced a slight decline, with total sales decreasing by 0.7% year-on-year to 133 trillion won (approximately $93.3 billion). Despite this downturn at the overall level, certain segments of the market showcased positive growth. Notably, the pharmaceutical sector reported an increase in revenue, reaching 53.8 trillion won, representing a growth of 6.1% compared to the previous year. This robust performance underscores the resilience of this segment amid broader industry challenges. The cosmetics industry also benefitted from a favorable market environment, achieving sales of 42 trillion won and a significant increase of 7.9%. In contrast, the medical devices sector witnessed a more pronounced decline, with sales plummeting by 15.7% to 37.9 trillion won. This diverging performance reflects varying market dynamics impacting different sectors within the bio-health industry. Furthermore, research and development (R&D) spending surged in this period, with an 18.5% increase to 7.4 trillion won, indicating a strong commitment to innovation and growth. The workforce in the bio-health industry also expanded, totaling 352, 784 employees, which represents a 3.1% increase from the previous year, highlighting a continued focus on human capital as a critical asset.

  • 2-2. 2024 Health Exports Surge

  • In 2024, South Korea's health exports surged significantly, reaching $25.26 billion, reflecting a year-on-year increase of 15.8%. This remarkable growth was primarily driven by record-high shipments in biopharmaceuticals and cosmetics. Biopharmaceutical exports alone contributed substantially to this growth, with exports to North America and Europe witnessing a notable rise. Specifically, export values for biopharmaceuticals totaled $9.27 billion, a 22.7% increase from the previous year. Among these, exports to the U.S. reached $1.49 billion, highlighting the U.S. as the top destination for Korean pharmaceuticals. Additionally, Hungary showcased impressive growth, with a staggering 306.3% increase, further illustrating the expanding footprint of Korean biopharmaceuticals in global markets. The cosmetics sector also achieved landmark figures, surpassing the $10 billion mark in exports for the first time, driven by strong demand for basic skincare products and color cosmetics from markets such as the U.S., Japan, and Hong Kong. This solid performance indicates a strategic diversification of Korea's export portfolio and responsive adaptation to shifting global demands.

  • 2-3. Pharmaceutical and Cosmetics Drivers

  • The stellar performance of South Korea's health exports in 2024 can be attributed largely to three key drivers within the pharmaceutical and cosmetics sectors. First, the biopharmaceutical segment's growth was significantly bolstered by its competitive pricing and advanced technology solutions, which have gained favorable reception in foreign markets, particularly in the U.S. and parts of Europe. Second, the diversification of export markets has further fueled growth, moving beyond traditional partners to include a wider range of countries. For example, biopharmaceutical exports to Hungary increased exponentially, which emphasizes the strategic expansion efforts of Korean firms into emerging markets. Lastly, the cosmetics sector's performance can be attributed to innovative product offerings and strong branding that resonate with global trends in beauty and personal care. Korean cosmetics are increasingly recognized for their quality and efficacy, which has captivated a growing consumer base across various international markets. The combined impact of these drivers not only signifies robust growth but also positions the South Korean bio-health industry favorably for ongoing and future expansion in the global marketplace.

3. Growth Projections and Global Positioning

  • 3-1. 2030 Market Ranking Forecast

  • As of May 8, 2025, there is a burgeoning optimism surrounding South Korea's biohealth industry, which is forecasted to reach a global market ranking of eighth by 2030. According to a report released by the Korea Health Industry Development Institute (KHIDI) on April 25, 2025, this anticipated ranking is attributed to an annual growth rate of nearly 9%, projecting the market size to reach approximately $370.3 billion by that year. This growth trajectory reflects both the evolution of domestic capabilities and the integration of advanced technologies, notably artificial intelligence and big data, into the healthcare sector. Historical data reveals that as of 2023, the biohealth sector was valued at $215.9 billion, accounting for 1.6% of the global market and ranking 11th worldwide. In particular, South Korea has positioned itself as a strong competitor in pharmaceuticals, medical devices, cosmetics, and healthcare services, with aspirations to continue this upward momentum well into the next decade.

  • 3-2. CAGR and Market Size Outlook

  • The Compound Annual Growth Rate (CAGR) for South Korea's biohealth industry is projected at 8.7% from 2023 to 2030, an increase from the average annual growth of 5.7% experienced from 2019 to 2023. The KHIDI report highlights this shift as a significant turning point for the sector, driven primarily by technological advancements in areas such as digital therapeutics and AI-assisted medical applications. By 2030, if growth proceeds as anticipated, South Korea will surpass other countries like Brazil and the United Kingdom, solidifying its place among the top eight globally recognized biohealth markets. This escalation is not only pivotal for enhancing the domestic economy but also for positioning South Korea as a leader in healthcare innovation on an international scale, catering to both local and global needs. The projected market size underscores the strategic importance of continued investments in research and development, as well as public-private partnerships, to harness this anticipated growth and every opportunity it presents.

4. Major Corporate Investments Amid Industry Downturn

  • 4-1. Samsung Biologics’ Investment Strategy

  • In light of the broader biotech industry downturn, Samsung Biologics has demonstrated a proactive investment strategy, fueled by a robust financial position. As of May 6, 2025, the company reported total cash and cash equivalents of KRW 1.2986 trillion, although this figure has decreased from KRW 2.018 trillion a year earlier. The decline can be attributed to substantial debt repayments totaling approximately KRW 800 billion, aimed at strengthening its financial structure. Despite the reduction in cash reserves, Samsung Biologics is significantly ramping up its capital expenditures.

  • In 2024, the company invested KRW 2.0012 trillion in facility expansions, representing a remarkable increase of 155.8% compared to its investments in 2023. A key development in this expansion is the full-scale operation of its Plant 5, which has increased its total production capacity to an impressive 784, 000 liters, making it the largest biopharmaceutical production facility worldwide. Looking ahead, Samsung Biologics plans to invest a total of KRW 7.5 trillion by 2032 to develop its second Bio Campus (Plants 5–8), with aspirations to further expand total capacity to 1.324 million liters. Internal discussions are also in progress regarding specialized facilities for innovative drug modalities, such as antibody-drug conjugates.

  • By leveraging its strong operating cash flow, Samsung Biologics has maintained a positive outlook amid a tightening investment climate for the industry at large.

  • 4-2. SK Bioscience’s Cash Deployment

  • Similar to its industry counterpart, SK Bioscience is also aggressively capitalizing on investment opportunities despite the subdued biotech market. As of the end of 2024, SK Bioscience's cash and cash equivalents amounted to KRW 1.1581 trillion, reflecting an 11.1% increase from the previous year. Notably, its net cash position stands at KRW 774.8 billion after accounting for borrowings, positioning SK Bioscience favorably in terms of financial liquidity, especially following the surge in operating profits during the COVID-19 pandemic.

  • SK Bioscience has also been actively diversifying its portfolio through mergers and acquisitions (M&A). With substantial funds raised from its initial public offering (IPO) and its flourishing vaccine business, the company has strategically acquired overseas entities, including the German contract development and manufacturing organization (CDMO) IDT Biologika and a controlling interest in the U.S. biotech firm PinA BioSolutions. Furthermore, SK Bioscience plans to pursue additional investments in emerging global biotech firms to bolster its technological capabilities and expand its market reach.

  • A company spokesperson emphasized the importance of these strategic investments for enhancing competitiveness and establishing a foundation for SK Bioscience's ambitions to evolve into a global powerhouse in the biotech landscape.

5. Innovation through Digital Transformation

  • 5-1. Big Data in Healthcare Adoption

  • The integration of Big Data into the healthcare sector has emerged as a critical driver of innovation and operational efficiency. As of May 2025, the market size for Big Data in healthcare is valued at approximately USD 68.56 billion in 2023, with projections to expand significantly to USD 283.43 billion by 2032, growing at a compound annual growth rate (CAGR) of 16.78% from 2024 onwards. This exponential growth can be attributed to the increasing reliance on data-driven technologies for improving patient outcomes, enhancing operational efficiency, and supporting clinical decision-making processes. Hospitals and healthcare systems across the globe are increasingly adopting big data solutions to facilitate real-time patient monitoring and predictive analytics, which are instrumental in resource optimization and early disease detection. The utilization of electronic health records (EHRs) is a foundational element in this transformation, with over 96% of hospitals in the U.S. employing certified EHR systems, thereby creating a rich repository of structured and unstructured healthcare data. This data underpins advances in personalized medicine, preventive healthcare, and targeted treatment plans. Significant investments are being made to develop the necessary infrastructure to support big data initiatives, such as predictive analytics tools that help anticipate patient admissions and manage chronic conditions effectively. The trend highlights a shift towards proactive healthcare, leveraging data insights to enhance patient care and streamline institutional workflows.

  • 5-2. ICT Integration in Life Sciences

  • Information and Communication Technology (ICT) is fundamentally reshaping the life sciences sector, facilitating rapid advancements in patient care and research processes. As of May 2025, the ICT sector within healthcare is projected to grow at a CAGR of 14.58% through 2030. This growth underscores the essential role of digital transformation in enhancing operational agility and enabling scalable research frameworks. Organizations in the healthcare field are increasingly prioritizing patient-centric care through the deployment of advanced ICT solutions. At the forefront are applications that support electronic health records, telemedicine, and data-driven diagnostics, all aimed at improving care delivery models. The ongoing integration of ICT encompasses a variety of domains including application development, data management, information security, and communication technologies. These innovations are critical for accelerating research outcomes and driving long-term value. The utilization of AI and secure communication platforms is pivotal in creating interconnected healthcare ecosystems, enhancing functionalities such as clinical trial automation and real-time data sharing between providers and patients. Major players, including Oracle, Microsoft, and IBM, are leading the charge in developing interoperable systems that promise to redefine operational standards and patient engagement strategies across the sector.

6. Industry Collaboration and Events

  • 6-1. Bio Korea 2025 Overview

  • Bio Korea 2025, the largest health and pharmaceutical industry trade fair in South Korea, commenced on May 7, 2025, in Seoul at the Convention and Exhibition Center (COEX). The event celebrates its 20th anniversary and is designed to facilitate networking and collaboration among industry stakeholders. This year's theme, "Innovation and Cooperation, Shaping the Future Together, " reflects the emphasis on collaborative efforts to drive advancements in the biohealth sector. The trade fair brought together approximately 750 companies from around the globe, showcasing a diverse range of technological innovations and trends. Organizers anticipated about 30, 000 visitors exploring the event, which includes 429 exhibition booths run by 323 participating companies, providing a substantial platform for knowledge exchange and collaboration.

  • The event featured a business partnering program involving prominent global firms, including Johnson & Johnson, Novo Nordisk, Merck Sharp & Dohme, alongside local representatives like Celltrion Inc. and SK Bioscience. This collaboration is pivotal as it aligns with South Korea's strategic goal to become a global hub for biohealth. The South Korean government pledged significant support, amounting to 1 trillion won (approximately $721 million), aimed at bolstering research and development projects, establishing a K-bio vaccine fund, and enhancing export capabilities. Government officials underscored their commitment to improving regulations and fostering specialized talent as part of their broader initiative to support the biohealth ecosystem.

  • 6-2. Global Participation and Technology Showcases

  • One of the highlights of Bio Korea 2025 is its focus on cutting-edge technologies, particularly those driven by artificial intelligence (AI) and biotechnology. The event served as a crucial platform for showcasing innovations in areas such as new modalities of treatment and anti-aging therapies, which have become increasingly relevant in contemporary healthcare discussions. The influx of international participation this year underscores the growing interest and investment in South Korea's biohealth sector, reinforcing its reputation as a leader in biopharmaceutical and healthcare advancements.

  • As biohealth industries worldwide continue to evolve, events like Bio Korea 2025 play a critical role in fostering global collaboration. Exhibitors and attendees have the opportunity to engage in dialogues about the future trends that will shape the industry. Notably, discussions surrounding the integration of AI in healthcare and the development of new treatment modalities were prominent themes, indicative of the sector's shift towards technological integration. The government's proactive measures, including financial support for innovation and regulatory improvements, are aimed at enhancing these developments further.

  • In summary, Bio Korea 2025 not only celebrated milestones achieved in the past two decades but also set the stage for future advancements in the biohealth sector, positioning South Korea as a prominent player on the global stage. As the industry looks forward, ongoing participation in global trade fairs like Bio Korea will be essential for maintaining momentum and fostering innovation in medical technologies.

Conclusion

  • In summary, as of May 8, 2025, South Korea's medical and bio-health industry remains resilient, navigating past challenges with notable achievements in export growth and strategic corporate investments. Despite the slight downturn in domestic sales during 2023, the industry witnessed a robust export surge in 2024, signaling a recovery aligned with the global appetite for Korean biomedical innovations. Companies like Samsung Biologics and SK Bioscience illustrate the industry's commitment to overcoming short-term volatility, as their aggressive investment strategies reflect a strong belief in the sector's long-term success.

  • The projection of South Korea entering the ranks of the world’s top eight biohealth markets by 2030 brings forth significant implications for stakeholders in the sector. This anticipated growth emphasizes the necessity for enhanced public-private partnerships, which can catalyze research and development initiatives and rapidly advance AI-driven healthcare solutions. Maintaining momentum through industry events such as Bio Korea and fostering global collaborations will be paramount in nurturing ongoing innovation and sustaining competitive advantages in the marketplace. The current landscape positions the South Korean bio-health sector at a strategic juncture, underscoring that proactive engagement and investment in emerging technologies will be essential as the industry evolves further.

Glossary

  • Biohealth Industry: The biohealth industry encompasses sectors related to healthcare, pharmaceuticals, and biotechnology. As of May 2025, South Korea's biohealth industry is recognized for its rapid growth and innovation. The sector includes areas such as pharmaceuticals, medical devices, and cosmetics, aiming to improve health outcomes and drive economic growth.
  • Samsung Biologics: Samsung Biologics is a leading biopharmaceutical company in South Korea, renowned for its large-scale biologics production facilities. As of May 2025, the company is undergoing significant capital investments, aiming to expand its production capacity and technological capabilities amidst industry volatility.
  • SK Bioscience: SK Bioscience is a prominent biotechnology firm in South Korea, focusing on developing vaccines and advanced biopharmaceuticals. As of early May 2025, the company is strategically enhancing its portfolio through mergers and acquisitions while maintaining a strong cash position to capitalize on emerging opportunities.
  • Export Surge: The term refers to a notable increase in the export of goods. In 2024, South Korea experienced a significant export surge in the biohealth sector, achieving $25.26 billion, predominantly boosted by biopharmaceuticals and cosmetics. This growth reflects rising global demand for South Korean health products.
  • Compound Annual Growth Rate (CAGR): CAGR is a metric used to measure the growth rate of an investment over a specified period, assuming the investment grows at a steady rate. The current projected CAGR for South Korea’s biohealth industry is approximately 8.7% from 2023 to 2030, reflecting anticipated robust expansion.
  • Big Data: Big Data refers to the vast volumes of structured and unstructured data generated daily. In healthcare, as of May 2025, its integration is transforming patient care through enhanced analytics, predictive modeling, and operational efficiency, with the market projected to grow significantly by 2032.
  • ICT (Information and Communication Technology): ICT encompasses technologies that enable communication and the management of information. In the healthcare sector, ICT is rapidly advancing with a projected CAGR of 14.58% through 2030, enhancing operational frameworks and patient care models.
  • Bio Korea 2025: Bio Korea 2025 is the largest health and pharmaceutical trade fair in South Korea, taking place from May 7, 2025. This event encourages networking and collaboration within the biohealth sector and showcases innovations from various global participants.
  • R&D (Research and Development): R&D refers to activities undertaken by companies to innovate and develop new products or processes. In the Korean biohealth sector, significant R&D spending reflects the industry's commitment to technological advancements and enhancing health solutions.
  • Pharmaceuticals: Referring to medicinal drugs, pharmaceuticals accounted for a significant portion of South Korea's biohealth market, generating revenues of 53.8 trillion won in 2023, which marked a growth of 6.1% year-over-year despite industry challenges.
  • Market Size: Market size represents the total potential sales of a product or industry. The biohealth market in South Korea is projected to reach approximately $370.3 billion by 2030, signifying its anticipated expansion and growing global importance.

Source Documents